Skye Bioscience Inc. is a biotechnology company focused on the development of innovative therapeutics derived from cannabis
The company leverages its expertise in cannabinoid research to create new treatment options targeting various medical conditions, with a particular emphasis on addressing unmet needs in the fields of pain management and ocular diseases. By harnessing the potential of cannabinoid compounds, Skye aims to enhance patients' quality of life through breakthrough therapies that utilize natural plant-based ingredients. The company's mission revolves around advancing scientific understanding and unlocking the therapeutic benefits of cannabis to improve health outcomes.
Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Skye Bioscience is developing a peripheral restricted CB1 antibody to treat obesity by restoring leptin sensitivity and increasing fat metabolism, while avoiding the CB1-induced THC/neuro side effects. This has significant potential.
Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.
Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose. However, investors reacted to limited gains at higher doses. Corbus Pharmaceuticals and Skye Bioscience stocks dropped as all three companies explore CB1 inhibition in obesity treatment.
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQSKYE). Investors who purchased Skye securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/SKYE.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQSKYE). Investors who purchased Skye securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/SKYE.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQSKYE) for violations of the securities laws.
BOSTON and SAN DIEGO, July 24, 2024 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leader in at-home sleep monitoring and computational neurodiagnostics, today announced a strategic collaboration with Skye Bioscience, Inc. (Nasdaq: SKYE), a pharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, to enhance its upcoming CBEYOND™ Phase 2 clinical trial of Nimacimab. This partnership will incorporate sleep quality and sleep apnea endpoints via the Beacon Platform and the FDA 510(k)-cleared Dreem 3S EEG device to better understand the comprehensive impact of Nimacimab on patients with obesity.
